Effects of PGH2 and PGD2 on CRTH2 and DP receptors in primary cells and co-expressed in HEK293 cells by Sedej, Miriam et al.
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
BMC Pharmacology
Open Access Meeting abstract
Effects of PGH2 and PGD2 on CRTH2 and DP receptors in primary 
cells and co-expressed in HEK293 cells
Miriam Sedej, Wolfgang Platzer, Anela Vukoja, Rufina Schuligoi, 
Bernhard A Peskar, Ákos Heinemann and Maria Waldhoer*
Address: Institute of Experimental and Clinical Pharmacology, Medical University of Graz, 8010 Graz, Austria
Email: Maria Waldhoer* - maria.waldhoer@meduni-graz.at
* Corresponding author    
Prostaglandin (PG) D2 is a PGH2 metabolite deriving from
the cyclooxygenase pathway and the major prostanoid
released from activated human mast cells. The biological
effects of PGD2 are mediated by the G protein-coupled
receptors (GPCRs) D-type prostanoid receptor (DP) and
the chemoattractant receptor-homologous molecule
expressed on Th2 cells (CRTH2). Eosinophils, important
effector cells in allergy, express both receptors. Activation
of CRTH2 has been shown to result in pro-inflammatory
responses, while the role of DP in allergic inflammation is
still unclear. In this study we show that PGH2 selectively
stimulates human peripheral blood eosinophils and
basophils, but not neutrophils, and this effect is prevented
by the CRTH2 receptor antagonist, Cay10471. In chemo-
taxis assays, eosinophils showed a pronounced migratory
response towards PGH2, while eosinophil degranulation
was inhibited by PGH2. Moreover, collagen-induced
platelet aggregation was inhibited by PGH2 in platelet-rich
plasma, which was abrogated in the presence of the DP
antagonist, BWA868c. HEK293 cells transfected with
either human CRTH2 or DP responded with Ca2+ flux,
while untransfected HEK293 cells showed no response.
These data indicate that PGH2 causes activation of the
PGD2 receptors, CRTH2 and DP, even in the absence of
functional PGD synthase. In further experiments, CRTH2
and DP receptors were stably co-expressed in HEK293
cells as a tool to explore receptor signalling and to investi-
gate possible receptor heterodimerization. Data will be
shown that demonstrate possible combinatorial effects of
CRTH2 and DP to selective and non-selective agonists and
antagonists in Ca2+ signalling assays.
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